Relapsing Multiple Sclerosis

Showing 1 - 25 of 62

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Concentration of BRIUMVI™ (Ublituximab) in Breast Milk

Not yet recruiting
  • Relapsing Multiple Sclerosis
  • No intervention
  • (no location specified)
Nov 16, 2023

Relapsing Multiple Sclerosis, Multiple Sclerosis Trial (Placebo, Pirtobrutinib)

Not yet recruiting
  • Relapsing Multiple Sclerosis
  • Multiple Sclerosis
  • (no location specified)
Oct 24, 2023

Relapsing Multiple Sclerosis Trial in Fort Collins, Farmington (Ublituximab)

Recruiting
  • Relapsing Multiple Sclerosis
  • Ublituximab
  • Fort Collins, Colorado
  • +1 more
May 26, 2023

Ofatumumab in Portuguese Multiple Sclerosis Patients

Not yet recruiting
  • Relapsing Multiple Sclerosis
  • Ofatumumab
  • (no location specified)
Mar 30, 2023

Early Versus Late Ofatumumab Use in Austrian RMS-Patients Over 2

Not yet recruiting
  • Relapsing Multiple Sclerosis
  • Ofatumumab
  • (no location specified)
Mar 17, 2023

Relapsing Multiple Sclerosis Trial in Worldwide (fenebrutinib, )

Recruiting
  • Relapsing Multiple Sclerosis
  • Fullerton, California
  • +16 more
Jan 24, 2023

Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis Trial in United

Recruiting
  • Relapsing Multiple Sclerosis
  • +2 more
  • Autologous Hematopoietic Stem Cell Transplantation
  • Best Available Therapy (BAT)
  • Palo Alto, California
  • +20 more
Jan 25, 2023

COVID-19 Vaccine in Multiple Sclerosis Participants Treated With

Completed
  • Relapsing Multiple Sclerosis
  • Ofatumumab
  • Covid-19 vaccine
  • Phoenix, Arizona
  • +4 more
Jan 23, 2023

Relapsing Multiple Sclerosis Trial in Worldwide (Ofatumumab)

Recruiting
  • Relapsing Multiple Sclerosis
  • Ofatumumab
  • Cullman, Alabama
  • +165 more
Jan 13, 2023

Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis Trial in Worldwide (Ocrelizumab IV, Ocrelizumab SC,

Active, not recruiting
  • Relapsing Multiple Sclerosis
  • Primary Progressive Multiple Sclerosis
  • Ocrelizumab IV
  • +5 more
  • Tampa, Florida
  • +46 more
Jan 13, 2023

Relapsing Multiple Sclerosis Trial in Worldwide (Ofatumumab, Tetanus toxoid (TT) containing vaccine (Td, Tdap), 13-valent

Recruiting
  • Relapsing Multiple Sclerosis
  • Ofatumumab
  • +5 more
  • Birmingham, Alabama
  • +295 more
Jan 13, 2023

Relapsing Multiple Sclerosis Trial in Worldwide (fenebrutinib, teriflunomide, )

Recruiting
  • Relapsing Multiple Sclerosis
  • Homewood, Alabama
  • +156 more
Jan 5, 2023

Relapsing Multiple Sclerosis Trial in Worldwide (fenebrutinib, teriflunomide, )

Recruiting
  • Relapsing Multiple Sclerosis
  • Cullman, Alabama
  • +138 more
Jan 5, 2023

Relapsing Multiple Sclerosis Trial in Worldwide (Interferon beta-1a, Ocrelizumab-matching , Ocrelizumab)

Active, not recruiting
  • Relapsing Multiple Sclerosis
  • Interferon beta-1a
  • +3 more
  • Phoenix, Arizona
  • +140 more
Jan 2, 2023

Relapsing Multiple Sclerosis Trial in Worldwide (Evobrutinib, Placebo (match to Teriflunomide), Teriflunomide)

Active, not recruiting
  • Relapsing Multiple Sclerosis
  • Cullman, Alabama
  • +275 more
Nov 7, 2022

Relapsing Multiple Sclerosis Trial in Worldwide (Evobrutinib, Placebo (match to Teriflunomide), Teriflunomide)

Active, not recruiting
  • Relapsing Multiple Sclerosis
  • Mobile, Alabama
  • +278 more
Nov 7, 2022

Relapsing Multiple Sclerosis Trial in Worldwide (Remibrutinib, Teriflunomide)

Recruiting
  • Relapsing Multiple Sclerosis
  • Fullerton, California
  • +38 more
Aug 12, 2022

s in Patients With Relapsing Multiple Sclerosis

Recruiting
  • Relapsing Multiple Sclerosis
  • ofatumumab
  • +2 more
  • Untermeiting, Bayern, Germany
  • +35 more
Aug 12, 2022

Relapsing Multiple Sclerosis Trial in Beijing (Mitoxantrone Hydrochloride Liposome Injection)

Not yet recruiting
  • Relapsing Multiple Sclerosis
  • Mitoxantrone Hydrochloride Liposome Injection
  • Beijing, Beijing, China
    Xuanwu Hospital Capital Medical University
Aug 9, 2022

RMS Patients on Ofatumumab or Ocrelizumab inReal-World Setting

Recruiting
  • Relapsing Multiple Sclerosis
  • Ofatumumab
  • Ocrelizumab
  • Dubai, United Arab Emirates
    Novartis Investigative Site
Aug 8, 2022

Relapsing Multiple Sclerosis Trial in Worldwide (Remibrutinib, Teriflunomide)

Recruiting
  • Relapsing Multiple Sclerosis
  • Hanford, California
  • +41 more
Aug 5, 2022

Relapsing Multiple Sclerosis Trial in Australia, Canada, United States (CNM-Au8)

Active, not recruiting
  • Relapsing Multiple Sclerosis
  • Dallas, Texas
  • +6 more
Jun 2, 2022

Inflammatory Disease in Multiple Sclerosis

Active, not recruiting
  • Relapsing Multiple Sclerosis
  • Multiple Sclerosis
  • Cerebrospinal and Blood Serum Semaphorin 4A Levels
  • Portland, Oregon
    Providence St. Vincent Medical Center
May 19, 2022

Relapsing Multiple Sclerosis, Clinically Isolated Syndrome Trial in San Francisco (Ocrelizumab)

Recruiting
  • Relapsing Multiple Sclerosis
  • Clinically Isolated Syndrome
  • San Francisco, California
    University of California San Francisco
Apr 28, 2022

Relapsing Multiple Sclerosis Trial in Japan, Russian Federation (Ofatumumab, Matching of ofatumumab)

Completed
  • Relapsing Multiple Sclerosis
  • Toon-city, Ehime, Japan
  • +13 more
Apr 27, 2022